AKT as locus of fragility in robust cancer system

Ziv Radisavljevic1

  • 1Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. zradisavljevic@rics.bwh.harvard.edu

Insights

Targeting the AKT pathway, a critical "locus of fragility," can disrupt metastatic cancer

Area of Science:

  • Oncology
  • Systems Biology
  • Molecular Biology

Background:

  • Metastatic cancer exhibits robustness due to complex positive feedback loops.
  • Signaling pathways controlling cancer robustness have critical vulnerabilities or
  • loci of fragility.

Purpose of the Study:

  • To identify and target a key locus of fragility within cancer signaling pathways.
  • To investigate the role of the AKT pathway as a central vulnerability in metastatic cancer.

Main Methods:

  • Analysis of signaling pathways including PI3K/AKT/mTOR/RAN and VEGF/PI3K/AKT/NO/ICAM-1.
  • Investigating the impact of perturbations on the AKT pathway, specifically redox state modulation by catalase.

Main Results:

  • The AKT pathway is identified as a locus of fragility, crucial for cell cycle progression, migration, and angiogenesis.
  • Antioxidant catalase, by altering cellular redox state, disrupts AKT phosphorylation, leading to cascading pathway failure.
  • Targeting AKT abolishes signals from growth factors like VEGF, HGF, and HIF-1alpha.

Conclusions:

  • The AKT pathway represents a critical vulnerability in robust metastatic cancer signaling.
  • Simultaneous targeting of AKT and nitric oxide (NO) pathways offers a novel strategy for cancer chemotherapy.
  • This approach blocks proliferation, migration, and angiogenesis, promoting slow cancer eradication.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...